GSK plc (NYSE:GSK) Shares Purchased by Hantz Financial Services Inc.

Hantz Financial Services Inc. boosted its holdings in shares of GSK plc (NYSE:GSK) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 87,416 shares of the pharmaceutical company’s stock after buying an additional 7,858 shares during the quarter. Hantz Financial Services Inc.’s holdings in GSK were worth $2,956,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. FMR LLC increased its holdings in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC grew its position in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after buying an additional 870,449 shares in the last quarter. Primecap Management Co. CA increased its stake in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after buying an additional 342,365 shares during the period. Provident Trust Co. raised its holdings in GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after acquiring an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its stake in GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 0.8 %

NYSE:GSK opened at $35.35 on Friday. The company has a market capitalization of $73.27 billion, a PE ratio of 22.96, a P/E/G ratio of 1.31 and a beta of 0.63. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The stock’s 50 day moving average price is $34.01 and its 200 day moving average price is $37.73. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.